Latest News and Press Releases

WALTHAM, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...

On track with U.S. Phase 3 CHIASMA OPTIMAL trial; data now expected by mid-Q3 2019 Target enrollment completed in ongoing Phase 3 MPOWERED™ trial; data expected in 2H 2020 WALTHAM, Mass., June 27,...

Appoints pharma commercial veteran Raj Kannan as Chief Executive Officer Current CEO Mark Fitzpatrick to retain the role of President WALTHAM, Mass., June 05, 2019 (GLOBE NEWSWIRE) -- Chiasma,...

Chiasma recently completed enrollment of its CHIASMA OPTIMAL Phase 3 clinical trial of octreotide capsules, the first potential oral somatostatin analog for the maintenance treatment of...

WALTHAM, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...

WALTHAM, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...

WALTHAM, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...

WALTHAM, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...

WALTHAM, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...

WALTHAM, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...